Patents Assigned to Genesis Research and Development Corporation Limited
  • Publication number: 20080145313
    Abstract: Compositions for the treatment and/or prevention of cancer in a mammal by means of RNA interference are provided, together with methods for the use of such compositions. The compositions comprise a small interfering nucleic acid molecule (siNA) that suppresses expression of a target gene that: (a) is involved in an energy metabolism pathway, such as the glycolysis pathway, within a tumor cell; (b) is involved in the biosynthesis of nucleotides, in glycogen metabolism or is an electron carrier that works with ATP to provide metabolic energy; or (c) is involved in transport of sugars, amino acids, and/or water-soluble vitamins, control of intercellular pH, or drug transport within a tumor cell.
    Type: Application
    Filed: August 30, 2007
    Publication date: June 19, 2008
    Applicant: Genesis Research & Development Corporation Limited
    Inventors: James D. Watson, Elizabeth S. Visser, Jun Hiyama, llkka J. Havukkala, Glen Reid, Annette Lasham
  • Publication number: 20070110752
    Abstract: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide finction. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.
    Type: Application
    Filed: November 1, 2006
    Publication date: May 17, 2007
    Applicant: Genesis Research and Development Corporation Limited
    Inventors: J. Murison, Zhihui Cao
  • Publication number: 20070004666
    Abstract: Proteinaceous transcription factors that regulate the transcription of genes and/or the translation of messenger RNA encoding proteins involved in apoptosis, such as CD95 and p53, are disclosed, together with methods for the use of such transcription factors in the modulation of apoptotic cell death. Methods for regulating apoptosis have therapeutic and prophylactic applications for a variety of disorders, including cancer, viral and retroviral infections, neurodegenerative disorders, immune system dysfunction, and other disorders.
    Type: Application
    Filed: August 8, 2006
    Publication date: January 4, 2007
    Applicant: Genesis Research & Development Corporation Limited
    Inventors: Annette Lasham, James Watson
  • Publication number: 20060183895
    Abstract: Novel isolated polynucleotides and polypeptides associated with the lignin biosynthetic pathway are provided, together with genetic constructs including such sequences. Methods for the modulation of lignin content, lignin structure and lignin composition in target organisms are also disclosed, the methods comprising incorporating one or more of the polynucleotides of the present invention into the genome of a target organism.
    Type: Application
    Filed: April 3, 2006
    Publication date: August 17, 2006
    Applicants: Genesis Research & Development Corporation Limited, Rubicon Forests Holdings Limited
    Inventors: Leonard Bloksberg, Iikka Havukkala
  • Patent number: 7083791
    Abstract: Isolated fibroblast growth factor receptor (FGFR5) polypeptides and polynucleotides encoding such polypeptides are provided. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to and agonize or antagonize FGFR5 polypeptide function. Specific binding molecules include antibodies, functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5 and, thus, are effective agents suitable for the treatment of diseases such as osteopontin-mediated autoimmune disease, such as systemic lupus erythematosus, bone disorders including osteoporosis and osteopetrosis, and cancers, including cellular carcinomas such as hepatocellular carcinomas.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: August 1, 2006
    Assignee: Genesis Research & Development Corporation Limited
    Inventors: Matthew Sleeman, J. Greg Murison
  • Publication number: 20060115483
    Abstract: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.
    Type: Application
    Filed: June 15, 2005
    Publication date: June 1, 2006
    Applicant: Genesis Research and Development Corporation Limited
    Inventors: Matthew Sleeman, J. Murison, Zhihui Cao
  • Publication number: 20050202437
    Abstract: Novel polynucleotides isolated from Lactobacillus rhamnosus, as well as oligonucleotide probes and primers, genetic constructs comprising the polynucleotides, biological materials, including plants, microorganisms and multicellular organisms incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for using the polynucleotides and polypeptides are disclosed.
    Type: Application
    Filed: August 28, 2003
    Publication date: September 15, 2005
    Applicants: GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED, VIALACTIA BIOSCIENCES (NZ) LIMITED
    Inventors: Matthew Glenn, Ilkka Havukkala, Mark Lubbers, James Dekker
  • Publication number: 20050112642
    Abstract: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.
    Type: Application
    Filed: September 29, 2004
    Publication date: May 26, 2005
    Applicant: GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED
    Inventors: Matthew Sleeman, J. Murison, Zhihui Cao
  • Publication number: 20050026162
    Abstract: Novel isolated vascular tissue-specific plant polynucleotide promoter sequences are provided, together with genetic constructs comprising such polynucleotides. Methods for using such constructs in modulating the transcription of DNA sequences of interest are also disclosed, together with transgenic plants comprising such constructs.
    Type: Application
    Filed: November 6, 2003
    Publication date: February 3, 2005
    Applicants: Genesis Research and Development Corporation Limited, Rubicon Forests Holdings Limited
    Inventors: Ranjan Perera, Stephen Rice, Clare Eagleton
  • Publication number: 20050009750
    Abstract: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.
    Type: Application
    Filed: July 6, 2004
    Publication date: January 13, 2005
    Applicant: GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED
    Inventors: Matthew Sleeman, J. Murison, Zhihui Cao
  • Publication number: 20040247622
    Abstract: Methods for the prevention and treatment of disorders, including disorders of the skin and respiratory system, such as infection with mycobacteria such as M. tuberculosis or M. avium, sarcoidosis, asthma, allergic rhinitis, allergic dermatitis and lung cancers are provided, such methods comprising administering a composition comprising at least one derivative of delipidated and deglycolipidated M. vaccae cells.
    Type: Application
    Filed: April 16, 2004
    Publication date: December 9, 2004
    Applicant: GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED
    Inventors: James D. Watson, Paul L.J. Tan, Ross L. Prestidge, Nevin Abernethy
  • Patent number: 6797271
    Abstract: Isolated polynucleotides and polypeptides derived from mammalian fsn -/-lymph node stromal cells are provided, together with expression vectors and host cells comprising such isolated polynucleotides. Methods for the use of such polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: September 28, 2004
    Assignee: Genesis Research & Development Corporation Limited
    Inventors: Matthew Sleeman, Nevin Abernethy, James Greg Murison
  • Patent number: 6768041
    Abstract: Novel isolated polynucleotides that encode polypeptides involved in plant cell signaling are provided, together with genetic constructs comprising such polynucleotides. Methods for using such constructs for the modulation of cell signaling in plants are also disclosed, together with transgenic plants comprising such constructs.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: July 27, 2004
    Assignee: Genesis Research and Development Corporation Limited
    Inventors: Timothy Strabala, Nicolaas Nieuwenhuizen
  • Patent number: 6716430
    Abstract: Polypeptides and polynucleotides isolated from Mycobacterium vaccae are provided, together with compositions comprising such polypeptide and polynucleotides, and methods for their use in the enhancement of immune responses to heterologous antigens.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: April 6, 2004
    Assignee: Genesis Research and Development Corporation Limited
    Inventor: Alain Delcayre
  • Publication number: 20040058849
    Abstract: Isolated fibroblast growth factor receptor (FGFR5) polypeptides and polynucleotides encoding such polypeptides are provided. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to and agonize or antagonize FGFR5 polypeptide function. Specific binding molecules include antibodies, functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5 and, thus, are effective agents suitable for the treatment of diseases such as osteopontin-mediated autoimmune disease, such as systemic lupus erythematosus, bone disorders including osteoporosis and osteopetrosis, and cancers, including cellular carcinomas such as hepatocellular carcinomas.
    Type: Application
    Filed: July 3, 2003
    Publication date: March 25, 2004
    Applicant: GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED
    Inventors: Matthew Sleeman, J. Greg Murison
  • Patent number: 6653528
    Abstract: Novel isolated polynucleotides associated with the lignin biosynthetic pathway are provided, together with constructs including such sequences. Methods for the modulation of lignin content, lignin structure and lignin composition in target organisms are also disclosed, the methods comprising incorporating one or more of the polynucleotides of the present invention into the genome of a target organism.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: November 25, 2003
    Assignees: Genesis Research & Development Corporation Limited, Rubicam Forests Industries Limited
    Inventors: Leonard N. Bloksberg, Ilkka Havukkala
  • Publication number: 20030147861
    Abstract: Methods and compositions for the modification of immune response by modulating of the Notch signaling pathway are provided, together with methods for the treatment of disorders characterized by the presence of an unwanted immune response. Such compositions comprise components derived from Mycobacteria, such as Mycobacterium vaccae.
    Type: Application
    Filed: July 25, 2002
    Publication date: August 7, 2003
    Applicant: Genesis Research and Development Corporation Limited
    Inventors: James D. Watson, Paul L.J. Tan, Nevin Abernethy
  • Publication number: 20030143676
    Abstract: Isolated fibroblast growth factor receptor polypeptides and polynucleotides encoding such polypeptides are provided, together with expression vectors and host cells comprising such isolated polynucleotides. Methods for the use of such polypeptides and polynucleotides are also provided.
    Type: Application
    Filed: May 28, 2002
    Publication date: July 31, 2003
    Applicant: Genesis Research and Development Corporation Limited
    Inventors: Lorna Strachan, Matthew Sleeman, Nevin Abernethy, Rene Onrust, Krishanand Kumble, James Greg Murison
  • Patent number: 6573095
    Abstract: Isolated polynucleotides encoding polypeptides expressed in mammalian skin cells are provided, together with expression vectors and host cells comprising such isolated polynucleotides. Methods for the use of such polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: June 3, 2003
    Assignee: Genesis Research & Development Corporation Limited
    Inventor: Lorna Strachan
  • Publication number: 20030101478
    Abstract: Novel isolated plant polynucleotide promoter sequences are provided, together with genetic constructs comprising such polynucleotides. Methods for using such constructs in modulating the transcription of DNA sequences of interest are also disclosed, together with transgenic plants comprising such constructs.
    Type: Application
    Filed: April 30, 2002
    Publication date: May 29, 2003
    Applicant: Genesis Research and Development Corporation Limited
    Inventors: Ranjan Perera, Stephen Rice, Marion Wood, Clare Eagleton, Elizabeth Visser